Immunovant
Alex Verdone is a seasoned professional in clinical development and business operations, currently serving as Sr Director of Clinical Development and Chief of Staff to the Chief Medical Officer at Immunovant since March 2020. Prior experience includes roles as Sr Director of Clinical Development Operations and Director of Clinical Operations at Immunovant, as well as Director and Senior Manager of Business Operations at Roivant Sciences from 2016 to 2020. Earlier experience includes a position as Summer Associate at Founders Fund and roles at Credit Suisse and Citi, focusing on leveraged and acquisition finance and portfolio management, respectively. Alex holds an M.B.A. from The Wharton School and a B.A. in Economics and International Public Policy from the University of North Carolina at Chapel Hill.
This person is not in the org chart
Immunovant
6 followers
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.